Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice

Author:

Badhai Jitendra1ORCID,Pandey Gaurav Kumar1,Song Ji-Ying2,Krijgsman Oscar3,Bhaskaran Rajith1,Chandrasekaran Gayathri1,Kwon Min-chul4,Bombardelli Lorenzo1,Monkhorst Kim5ORCID,Grasso Cristoforo4,Zevenhoven John4,van der Vliet Jan4,Cozijnsen Miranda4,Krimpenfort Paul4,Peeper Daniel3,van Lohuizen Maarten1,Berns Anton1

Affiliation:

1. Oncode Institute, Division of Molecular Genetics, The Netherlands Cancer Institute, Amsterdam, Netherlands

2. Department of Experimental Animal Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands

3. Oncode Institute, Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands

4. Division of Molecular Genetics, The Netherlands Cancer Institute, Amsterdam, Netherlands

5. Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands

Abstract

We have generated mouse models of malignant mesothelioma (MM) based upon disruption of the Bap1, Nf2, and Cdkn2ab tumor suppressor loci in various combinations as also frequently observed in human MM. Inactivation of all three loci in the mesothelial lining of the thoracic cavity leads to a highly aggressive MM that recapitulates the histological features and gene expression profile observed in human patients. The tumors also show a similar inflammatory phenotype. Bap1 deletion alone does not cause MM but dramatically accelerates MM development when combined with Nf2 and Cdkn2ab (hereafter BNC) disruption. The accelerated tumor development is accompanied by increased Polycomb repression and EZH2-mediated redistribution of H3K27me3 toward promoter sites with concomitant activation of PI3K and MAPK pathways. Treatment of BNC tumor–bearing mice with cisplatin and pemetrexed, the current frontline treatment, prolongs survival. This makes the autochthonous mouse model described here very well suited to explore the pathogenesis of MM and validate new treatment regimens for MM, including immunotherapy.

Funder

Dutch Cancer Society

European Research Council

Seventh Framework Program

Publisher

Rockefeller University Press

Subject

Immunology,Immunology and Allergy

Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3